Dren Bio Raises $350 Million for Dibotatug Development

The funding supports late-stage clinical trials and a planned commercial launch for the CD94-targeting antibody therapy.

Updated on Oct. 29, 2026 in Biotech

Isometric editorial illustration of a sterile glass laboratory pipette and dish, representing pharmaceutical innovation. — Dren Bio secured $350 million in private financing to accelerate late-stage clinical trials and commercial development for its lead antibody therapy, dibotatug. AI Illustration. Upload story photo >

Live Poll

Does large-scale private investment in biotech companies effectively improve the development of new medical treatments?

Dren Bio has closed an oversubscribed $350 million private financing round to advance its lead antibody therapeutic, dibotatug. The company plans to use the capital to support late-stage clinical trials, regulatory submissions, and a commercial launch for the drug.

Why it matters

The funding accelerates the late-stage development of dibotatug for cytotoxic T-cell lymphoma and large granular lymphocytic leukemia. It also enables Dren Bio to expand its proprietary antibody platform into additional disease indications.

Dren Bio has dosed more than 300 patients in clinical studies for dibotatug, a monoclonal antibody targeting CD94. The company utilizes a proprietary Targeted Myeloid Engager and Phagocytosis Platform to develop its pipeline of antibody therapeutics.

The players

Dren Bio

A San Carlos-based biotech company focused on oncology treatments using its proprietary Targeted Myeloid Engager and Phagocytosis Platform.

Juvia Group

An investment firm that co-led the financing and is staffed by partners with a track record of $15 billion in cumulative capital raised.

Lightspeed Venture Partners

A global venture capital firm managing $65 billion in assets that co-led this latest financing round.

The details

Dibotatug is a monoclonal antibody — a laboratory-made protein that mimics the immune system's ability to fight pathogens — designed to target CD94. The company's platform functions by engaging myeloid cells — a type of white blood cell — to initiate phagocytosis, the process where cells engulf and eliminate targeted pathogens or diseased cells. This approach aims to provide a precise method for addressing malignant cell populations in lymphoma and leukemia.

Dren Bio was founded in 2019.
Sanofi acquired the platform lead program DR-0201 in May 2025.
Dren Bio announced the $350 million financing on October 29, 2026.

The Tech Race

Dren Bio continues to scale its proprietary Targeted Myeloid Engager and Phagocytosis Platform following the divestiture of its DR-0201 program to Sanofi in 2025. This $350 million injection positions the company to maintain its competitive stance in the crowded monoclonal antibody space.

The clinical progression of dibotatug is currently limited to patients enrolled in trials for cytotoxic T-cell lymphoma and large granular lymphocytic leukemia. Following this funding, future availability for these therapies remains dependent on successful regulatory review and subsequent commercial launch.

The takeaway

Dren Bio is moving its lead oncology candidate toward the final stages of the regulatory process. Watch for the company's next formal filing with federal health authorities to confirm the timeline for the anticipated commercial launch of dibotatug.